Welcome to our dedicated page for Aardvark Therapeutics SEC filings (Ticker: AARD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aardvark Therapeutics, Inc. (Nasdaq: AARD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Aardvark uses forms such as Form 8-K to report material events, clinical and scientific updates, and quarterly financial results related to its pipeline of small-molecule therapies for Prader-Willi Syndrome and metabolic diseases.
Recent AARD filings include Form 8-K reports furnishing quarterly financial results and business updates, such as results for periods ended June 30 and September 30, along with commentary on research and development spending, general and administrative expenses, and cash, cash equivalents, and short-term investments. These filings often incorporate press releases as exhibits, giving investors a consolidated view of the company’s financial condition and development plans.
Aardvark also files 8-Ks under Items 7.01 and 8.01 to describe clinical and scientific milestones, including presentations at ObesityWeek, new preclinical data on ARD-201 and WE-868, and alignment with the U.S. Food and Drug Administration on protocol amendments to the Phase 3 HERO trial of ARD-101 in Prader-Willi Syndrome. Other 8-Ks document investor webinars reviewing ARD-101 and ARD-201 programs and provide access to slide presentations used in those events.
Through Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on topics such as clinical trial progress, regulatory interactions, financial trends, and risk factor references. Users can monitor new 8-Ks and, when available, 10-Q and 10-K reports to follow how Aardvark describes its pipeline, capital resources, and development risks over time.
For those researching AARD stock, this filings page offers a structured way to review the company’s official disclosures, including material events, scientific data announcements, and financial reporting, with tools that make complex SEC documents easier to interpret.
Aardvark Therapeutics, Inc. reported that it issued a press release on August 13, 2025 detailing its financial results for the second quarter ended June 30, 2025, along with updates on its drug development pipeline and overall business. The press release is provided as Exhibit 99.1 and gives the full results and operational commentary.
The company specifies that this press release and related information are being furnished rather than filed, meaning they are not subject to certain legal liabilities under the Securities Exchange Act and are not automatically incorporated into other securities law documents unless specifically referenced.
Aardvark Therapeutics disclosed via this Current Report that it issued a press release announcing new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. The company states the full text of the press release is filed as Exhibit 99.1 to the report and is incorporated by reference.
The filing does not include clinical data, quantitative results, financial statements, or a timetable for next steps; the report also identifies the registrant as an emerging growth company. Consult Exhibit 99.1 for the full press release text and any data not contained in the 8-K.